BeiGene, Ltd. (NASDAQ:BGNE) Given Average Recommendation of “Moderate Buy” by Analysts

BeiGene, Ltd. (NASDAQ:BGNE) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $253.69.

A number of equities analysts have commented on BGNE shares. Morgan Stanley restated an “overweight” rating and set a $300.00 price objective on shares of BeiGene in a research note on Tuesday, December 3rd. JPMorgan Chase & Co. boosted their price target on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, October 22nd. StockNews.com assumed coverage on shares of BeiGene in a research note on Sunday, January 19th. They set a “hold” rating on the stock. Finally, TD Cowen boosted their target price on shares of BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th.

Insider Buying and Selling at BeiGene

In other news, Director Bros. Advisors Lp Baker sold 1,037,017 shares of BeiGene stock in a transaction on Monday, December 9th. The shares were sold at an average price of $187.27, for a total transaction of $194,202,173.59. Following the transaction, the director now owns 791,493 shares in the company, valued at approximately $148,222,894.11. The trade was a 56.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Xiaodong Wang sold 40,468 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $190.10, for a total value of $7,692,966.80. The disclosure for this sale can be found here. Insiders have sold 1,119,245 shares of company stock worth $209,700,084 over the last quarter. Corporate insiders own 7.43% of the company’s stock.

Institutional Investors Weigh In On BeiGene

A number of institutional investors have recently made changes to their positions in BGNE. Blue Trust Inc. grew its stake in BeiGene by 156.3% during the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after purchasing an additional 75 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in shares of BeiGene in the 3rd quarter valued at $36,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of BeiGene during the 3rd quarter valued at $67,000. SG Americas Securities LLC acquired a new position in shares of BeiGene during the 3rd quarter valued at $105,000. Finally, PFG Investments LLC acquired a new stake in BeiGene in the third quarter worth $210,000. Institutional investors own 48.55% of the company’s stock.

BeiGene Stock Performance

The stock’s fifty day moving average price is $194.32 and its two-hundred day moving average price is $188.98. The firm has a market capitalization of $18.03 billion, a P/E ratio of -22.42 and a beta of 0.57. BeiGene has a twelve month low of $126.97 and a twelve month high of $248.16. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.26 million. During the same period in the prior year, the firm earned $2.01 EPS. The business’s revenue for the quarter was up 28.2% on a year-over-year basis. On average, equities research analysts predict that BeiGene will post -5.64 earnings per share for the current fiscal year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.